Scarica l'app Stockscreener
3.05
2.88%
0.10
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ESPR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.95
Aprire:
$2.95
Volume 24 ore:
3.32M
Relative Volume:
0.49
Capitalizzazione di mercato:
$727.95M
Reddito:
$116.33M
Utile/perdita netta:
$-209.25M
Rapporto P/E:
-1.4387
EPS:
-2.12
Flusso di cassa netto:
$-135.49M
1 W Prestazione:
+4.66%
1M Prestazione:
+8.78%
6M Prestazione:
+255.80%
1 anno Prestazione:
+22.87%
Intervallo 1D:
$2.95
$3.12
Intervallo di 1 settimana:
$2.66
$3.12
Portata 52W:
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Nome
Esperion Therapeutics Inc
Settore
Telefono
734-887-3903
Indirizzo
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Confronta ESPR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
3.045 | 699.35M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
118.91 | 51.07B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.31 | 44.42B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.91 | 42.75B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.09 | 27.86B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
473.07 | 20.44B | 3.08B | 1.24B | 1.07B | 25.61 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-18 | Iniziato | Goldman | Neutral |
| 2024-12-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-06-20 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-08-01 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2023-03-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-03-16 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | Ripresa | BofA Securities | Neutral |
| 2023-02-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-03-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | Downgrade | Stifel | Buy → Hold |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-02-12 | Downgrade | Jefferies | Buy → Hold |
| 2021-02-09 | Downgrade | Goldman | Neutral → Sell |
| 2021-01-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-11-10 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | Ripresa | JP Morgan | Underweight |
| 2020-08-11 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | Ripresa | BofA/Merrill | Buy |
| 2020-03-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-24 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2019-09-16 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-05-29 | Downgrade | Goldman | Neutral → Sell |
| 2019-05-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-03-13 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-07 | Reiterato | Needham | Strong Buy |
| 2018-12-13 | Iniziato | Goldman | Sell |
| 2018-10-29 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | Iniziato | BTIG Research | Buy |
| 2018-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-07-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-05-02 | Downgrade | BofA/Merrill | Buy → Underperform |
Mostra tutto
Esperion Therapeutics Inc Borsa (ESPR) Ultime notizie
Esperion stock rises after $90 million payment from Japan launch By Investing.com - Investing.com Nigeria
Esperion shares rise as Otsuka launches NEXLETOL in Japan - Investing.com India
Esperion shares rise as Otsuka launches NEXLETOL in Japan By Investing.com - Investing.com Australia
Esperion Partners with Otsuka to Launch NEXLETOL in Japan, Secures $90 Million Payment - Quiver Quantitative
Esperion (NASDAQ: ESPR) earns $90M with Otsuka's NEXLETOL launch in Japan market - Stock Titan
Is Esperion Therapeutics Inc. stock undervalued vs historical averages2025 Investor Takeaways & Smart Money Movement Tracker - newser.com
Is Esperion Therapeutics Inc. stock a safe investment in uncertain markets2025 Geopolitical Influence & AI Based Buy/Sell Signal Reports - newser.com
Will Esperion Therapeutics Inc. stock recover faster than marketTreasury Yields & Daily Profit Focused Screening - newser.com
Esperion: HLS Therapeutics (TSX:HLS) Secures Health Canada Clearance for NILEMDO® - Kalkine Media
Why Esperion Therapeutics Inc. is moving todayMarket Movement Recap & Expert Verified Movement Alerts - newser.com
Multi asset correlation models including Esperion Therapeutics Inc.Portfolio Return Summary & Low Drawdown Momentum Ideas - newser.com
Will Esperion Therapeutics Inc. stock outperform international peersQuarterly Earnings Summary & Stepwise Trade Execution Plans - newser.com
Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Esperion (NASDAQ: ESPR) to Present at Piper Sandler 37th Annual Healthcare Conference - Stock Titan
Can Esperion Therapeutics Inc. stock double in next 5 yearsJuly 2025 Retail & Safe Swing Trade Setups - newser.com
Will earnings trigger a reversal in Esperion Therapeutics Inc.2025 Technical Overview & Smart Investment Allocation Insights - newser.com
Esperion’s cholesterol drug Nilemdo receives Health Canada approval By Investing.com - Investing.com Nigeria
Esperion partner announces HLS Therapeutics received approval of Nilemdo for the reduction of LDL cholesterol in Canadians at risk of cardiovascular disease - MarketScreener
Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease - TradingView
HLS Therapeutics Receives Health Canada Approval to Market NILEMDO® for LDL-Cholesterol Reduction in Partnership with Esperion - Quiver Quantitative
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease - The Manila Times
Esperion Partner HLS Therapeutics Announces Approval of - GlobeNewswire
Why analysts raise outlook for Esperion Therapeutics Inc. (0ET) stockJuly 2025 Closing Moves & Scalable Portfolio Growth Ideas - newser.com
[Form 3] Esperion Therapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Relative strength of Esperion Therapeutics Inc. in sector analysisInflation Watch & Breakout Confirmation Alerts - newser.com
Why retail investors favor Esperion Therapeutics Inc. stockRisk Management & Free Expert Verified Stock Movement Alerts - newser.com
Is Esperion Therapeutics Inc. stock reversal real or fake2025 Growth vs Value & High Accuracy Buy Signal Tips - newser.com
Can volume confirm reversal in Esperion Therapeutics Inc.Swing Trade & Free Expert Verified Stock Movement Alerts - newser.com
Identifying reversal signals in Esperion Therapeutics Inc.July 2025 Macro Moves & Capital Protection Trading Alerts - newser.com
How to integrate Esperion Therapeutics Inc. into portfolio analysis toolsJuly 2025 Trends & Consistent Profit Trade Alerts - newser.com
Can Esperion Therapeutics Inc. stock deliver surprise earnings beatTrend Reversal & Free Reliable Trade Execution Plans - newser.com
Smart tools for monitoring Esperion Therapeutics Inc.’s price actionWeekly Profit Recap & Precise Swing Trade Entry Alerts - newser.com
Esperion Therapeutics Reports Strong Q3 Revenue Growth - MSN
ESPR | Esperion Therapeutics Inc. SEC Filings - MarketWatch
Esperion Therapeutics Inc Azioni (ESPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.04%
2.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):